Intrinsic value of Tabula Rasa HealthCare - TRHC

Previous Close

$66.85

  Intrinsic Value

$17.77

stock screener

  Rating & Target

str. sell

-73%

Previous close

$66.85

 
Intrinsic value

$17.77

 
Up/down potential

-73%

 
Rating

str. sell

We calculate the intrinsic value of TRHC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  215
  333
  497
  722
  1,018
  1,400
  1,879
  2,467
  3,175
  4,010
  4,979
  6,088
  7,338
  8,731
  10,266
  11,941
  13,755
  15,705
  17,787
  19,997
  22,334
  24,795
  27,378
  30,081
  32,905
  35,850
  38,916
  42,106
  45,424
  48,872
Variable operating expenses, $m
  197
  297
  437
  628
  880
  1,204
  1,612
  2,112
  2,713
  3,423
  4,233
  5,176
  6,239
  7,423
  8,728
  10,152
  11,695
  13,352
  15,122
  17,002
  18,989
  21,081
  23,277
  25,575
  27,976
  30,479
  33,086
  35,799
  38,619
  41,551
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  197
  297
  437
  628
  880
  1,204
  1,612
  2,112
  2,713
  3,423
  4,233
  5,176
  6,239
  7,423
  8,728
  10,152
  11,695
  13,352
  15,122
  17,002
  18,989
  21,081
  23,277
  25,575
  27,976
  30,479
  33,086
  35,799
  38,619
  41,551
Operating income, $m
  18
  36
  60
  94
  138
  195
  267
  355
  461
  586
  746
  912
  1,099
  1,308
  1,538
  1,789
  2,061
  2,353
  2,664
  2,996
  3,346
  3,714
  4,101
  4,506
  4,929
  5,370
  5,830
  6,308
  6,804
  7,321
EBITDA, $m
  40
  62
  93
  135
  191
  263
  352
  463
  595
  752
  934
  1,142
  1,376
  1,637
  1,925
  2,239
  2,580
  2,945
  3,335
  3,750
  4,188
  4,650
  5,134
  5,641
  6,171
  6,723
  7,298
  7,896
  8,518
  9,165
Interest expense (income), $m
  8
  1
  16
  38
  69
  111
  167
  239
  330
  441
  574
  732
  915
  1,124
  1,360
  1,622
  1,912
  2,228
  2,571
  2,938
  3,331
  3,748
  4,189
  4,653
  5,141
  5,651
  6,184
  6,739
  7,318
  7,920
  8,546
Earnings before tax, $m
  17
  20
  22
  25
  27
  28
  28
  26
  21
  12
  14
  -3
  -25
  -52
  -85
  -123
  -168
  -218
  -274
  -335
  -403
  -475
  -552
  -635
  -722
  -813
  -910
  -1,010
  -1,115
  -1,225
Tax expense, $m
  5
  5
  6
  7
  7
  8
  8
  7
  6
  3
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  13
  14
  16
  18
  20
  21
  20
  19
  15
  9
  10
  -3
  -25
  -52
  -85
  -123
  -168
  -218
  -274
  -335
  -403
  -475
  -552
  -635
  -722
  -813
  -910
  -1,010
  -1,115
  -1,225

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  299
  463
  692
  1,004
  1,416
  1,947
  2,613
  3,431
  4,415
  5,577
  6,925
  8,467
  10,206
  12,143
  14,278
  16,608
  19,131
  21,843
  24,738
  27,813
  31,063
  34,486
  38,078
  41,838
  45,765
  49,860
  54,125
  58,563
  63,176
  67,972
Adjusted assets (=assets-cash), $m
  299
  463
  692
  1,004
  1,416
  1,947
  2,613
  3,431
  4,415
  5,577
  6,925
  8,467
  10,206
  12,143
  14,278
  16,608
  19,131
  21,843
  24,738
  27,813
  31,063
  34,486
  38,078
  41,838
  45,765
  49,860
  54,125
  58,563
  63,176
  67,972
Revenue / Adjusted assets
  0.719
  0.719
  0.718
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
  0.719
Average production assets, $m
  89
  138
  206
  300
  423
  581
  780
  1,024
  1,317
  1,664
  2,066
  2,526
  3,045
  3,623
  4,260
  4,956
  5,708
  6,517
  7,381
  8,299
  9,269
  10,290
  11,362
  12,484
  13,656
  14,878
  16,150
  17,474
  18,851
  20,282
Working capital, $m
  -3
  -5
  -7
  -10
  -14
  -20
  -26
  -35
  -44
  -56
  -70
  -85
  -103
  -122
  -144
  -167
  -193
  -220
  -249
  -280
  -313
  -347
  -383
  -421
  -461
  -502
  -545
  -589
  -636
  -684
Total debt, $m
  40
  95
  173
  279
  419
  600
  826
  1,104
  1,439
  1,834
  2,292
  2,817
  3,408
  4,066
  4,792
  5,585
  6,442
  7,364
  8,349
  9,394
  10,499
  11,663
  12,884
  14,163
  15,498
  16,890
  18,340
  19,849
  21,418
  23,048
Total liabilities, $m
  102
  157
  235
  341
  481
  662
  889
  1,167
  1,501
  1,896
  2,355
  2,879
  3,470
  4,128
  4,854
  5,647
  6,505
  7,426
  8,411
  9,456
  10,561
  11,725
  12,946
  14,225
  15,560
  16,953
  18,403
  19,911
  21,480
  23,110
Total equity, $m
  198
  305
  457
  662
  935
  1,285
  1,725
  2,265
  2,914
  3,681
  4,571
  5,588
  6,736
  8,014
  9,423
  10,961
  12,627
  14,416
  16,327
  18,356
  20,502
  22,761
  25,131
  27,613
  30,205
  32,908
  35,723
  38,651
  41,696
  44,861
Total liabilities and equity, $m
  300
  462
  692
  1,003
  1,416
  1,947
  2,614
  3,432
  4,415
  5,577
  6,926
  8,467
  10,206
  12,142
  14,277
  16,608
  19,132
  21,842
  24,738
  27,812
  31,063
  34,486
  38,077
  41,838
  45,765
  49,861
  54,126
  58,562
  63,176
  67,971
Debt-to-equity ratio
  0.200
  0.310
  0.380
  0.420
  0.450
  0.470
  0.480
  0.490
  0.490
  0.500
  0.500
  0.500
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
Adjusted equity ratio
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660
  0.660

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  13
  14
  16
  18
  20
  21
  20
  19
  15
  9
  10
  -3
  -25
  -52
  -85
  -123
  -168
  -218
  -274
  -335
  -403
  -475
  -552
  -635
  -722
  -813
  -910
  -1,010
  -1,115
  -1,225
Depreciation, amort., depletion, $m
  22
  27
  33
  41
  53
  67
  85
  107
  134
  166
  188
  230
  277
  329
  387
  451
  519
  592
  671
  754
  843
  935
  1,033
  1,135
  1,241
  1,353
  1,468
  1,589
  1,714
  1,844
Funds from operations, $m
  35
  41
  49
  60
  72
  88
  106
  126
  149
  174
  198
  227
  252
  278
  303
  327
  351
  375
  397
  419
  440
  461
  481
  500
  520
  539
  559
  578
  598
  619
Change in working capital, $m
  -1
  -2
  -2
  -3
  -4
  -5
  -7
  -8
  -10
  -12
  -14
  -16
  -18
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -34
  -36
  -38
  -40
  -41
  -43
  -45
  -46
  -48
Cash from operations, $m
  36
  43
  52
  63
  76
  93
  112
  134
  159
  186
  212
  242
  270
  297
  324
  351
  377
  402
  426
  450
  473
  495
  517
  538
  559
  580
  602
  623
  645
  667
Maintenance CAPEX, $m
  -5
  -8
  -13
  -19
  -27
  -38
  -53
  -71
  -93
  -120
  -151
  -188
  -230
  -277
  -329
  -387
  -451
  -519
  -592
  -671
  -754
  -843
  -935
  -1,033
  -1,135
  -1,241
  -1,353
  -1,468
  -1,589
  -1,714
New CAPEX, $m
  -33
  -49
  -68
  -93
  -123
  -158
  -199
  -244
  -294
  -347
  -402
  -460
  -519
  -578
  -637
  -695
  -753
  -809
  -864
  -917
  -970
  -1,021
  -1,072
  -1,122
  -1,172
  -1,222
  -1,273
  -1,324
  -1,377
  -1,431
Cash from investing activities, $m
  -38
  -57
  -81
  -112
  -150
  -196
  -252
  -315
  -387
  -467
  -553
  -648
  -749
  -855
  -966
  -1,082
  -1,204
  -1,328
  -1,456
  -1,588
  -1,724
  -1,864
  -2,007
  -2,155
  -2,307
  -2,463
  -2,626
  -2,792
  -2,966
  -3,145
Free cash flow, $m
  -2
  -14
  -29
  -49
  -74
  -104
  -139
  -181
  -228
  -280
  -342
  -405
  -479
  -558
  -642
  -732
  -827
  -926
  -1,030
  -1,139
  -1,252
  -1,369
  -1,491
  -1,617
  -1,747
  -1,883
  -2,024
  -2,169
  -2,320
  -2,477
Issuance/(repayment) of debt, $m
  38
  55
  78
  106
  140
  180
  227
  278
  335
  395
  458
  524
  591
  659
  726
  792
  858
  922
  984
  1,045
  1,105
  1,164
  1,221
  1,278
  1,335
  1,392
  1,450
  1,509
  1,569
  1,630
Issuance/(repurchase) of shares, $m
  61
  93
  135
  188
  253
  330
  419
  521
  634
  758
  880
  1,020
  1,172
  1,330
  1,494
  1,661
  1,833
  2,007
  2,185
  2,365
  2,548
  2,734
  2,923
  3,116
  3,314
  3,516
  3,724
  3,939
  4,160
  4,390
Cash from financing (excl. dividends), $m  
  99
  148
  213
  294
  393
  510
  646
  799
  969
  1,153
  1,338
  1,544
  1,763
  1,989
  2,220
  2,453
  2,691
  2,929
  3,169
  3,410
  3,653
  3,898
  4,144
  4,394
  4,649
  4,908
  5,174
  5,448
  5,729
  6,020
Total cash flow (excl. dividends), $m
  97
  135
  184
  245
  319
  406
  507
  619
  741
  872
  996
  1,139
  1,284
  1,431
  1,577
  1,722
  1,864
  2,003
  2,139
  2,272
  2,401
  2,529
  2,654
  2,778
  2,902
  3,026
  3,151
  3,278
  3,409
  3,543
Retained Cash Flow (-), $m
  -74
  -108
  -151
  -206
  -272
  -350
  -440
  -540
  -649
  -767
  -890
  -1,020
  -1,172
  -1,330
  -1,494
  -1,661
  -1,833
  -2,007
  -2,185
  -2,365
  -2,548
  -2,734
  -2,923
  -3,116
  -3,314
  -3,516
  -3,724
  -3,939
  -4,160
  -4,390
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  23
  27
  32
  39
  47
  56
  67
  79
  92
  106
  106
  119
  112
  101
  84
  60
  31
  -4
  -46
  -93
  -146
  -205
  -269
  -338
  -412
  -491
  -573
  -661
  -752
  -847
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  22
  25
  28
  32
  36
  41
  45
  49
  53
  55
  50
  51
  43
  34
  25
  15
  7
  -1
  -7
  -12
  -15
  -17
  -18
  -17
  -16
  -14
  -12
  -10
  -8
  -6
Current shareholders' claim on cash, %
  95.3
  91.0
  87.2
  83.7
  80.6
  77.9
  75.4
  73.2
  71.2
  69.4
  67.8
  66.3
  65.0
  63.7
  62.5
  61.4
  60.4
  59.5
  58.6
  57.8
  57.0
  56.2
  55.5
  54.8
  54.2
  53.6
  53.0
  52.4
  51.8
  51.3

Tabula Rasa HealthCare, Inc. (Tabula Rasa), formerly CareKinesis, Inc., is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs. It also provides risk adjustment services, which help its clients to properly characterize a patient's acuity, or severity of health condition, and optimize the associated payments for care. The Company serves approximately 100 healthcare organizations that focus on populations with complex healthcare needs and extensive medication requirements. Its products and services are built around the Medication Risk Mitigation Matrix, or MRM Matrix.

FINANCIAL RATIOS  of  Tabula Rasa HealthCare (TRHC)

Valuation Ratios
P/E Ratio -185.3
Price to Sales 11.8
Price to Book 19.9
Price to Tangible Book
Price to Cash Flow 158.8
Price to Free Cash Flow 1111.7
Growth Rates
Sales Growth Rate 34.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 500%
Cap. Spend. - 3 Yr. Gr. Rate 43.1%
Financial Strength
Quick Ratio 1
Current Ratio 0.1
LT Debt to Equity 3.6%
Total Debt to Equity 8.9%
Interest Coverage 0
Management Effectiveness
Return On Assets 3%
Ret/ On Assets - 3 Yr. Avg. -0%
Return On Total Capital -11.7%
Ret/ On T. Cap. - 3 Yr. Avg. -7.2%
Return On Equity -22.6%
Return On Equity - 3 Yr. Avg. 75.8%
Asset Turnover 1.4
Profitability Ratios
Gross Margin 30.9%
Gross Margin - 3 Yr. Avg. 27.9%
EBITDA Margin 7.4%
EBITDA Margin - 3 Yr. Avg. 4.6%
Operating Margin -2.1%
Oper. Margin - 3 Yr. Avg. 2.1%
Pre-Tax Margin -6.4%
Pre-Tax Margin - 3 Yr. Avg. -4.9%
Net Profit Margin -6.4%
Net Profit Margin - 3 Yr. Avg. -4.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 16.7%
Payout Ratio 0%

TRHC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the TRHC stock intrinsic value calculation we used $134.546 million for the last fiscal year's total revenue generated by Tabula Rasa HealthCare. The default revenue input number comes from 0001 income statement of Tabula Rasa HealthCare. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our TRHC stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for TRHC is calculated based on our internal credit rating of Tabula Rasa HealthCare, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Tabula Rasa HealthCare.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of TRHC stock the variable cost ratio is equal to 95.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for TRHC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 39.9% for Tabula Rasa HealthCare.

Corporate tax rate of 27% is the nominal tax rate for Tabula Rasa HealthCare. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the TRHC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for TRHC are equal to 41.5%.

Life of production assets of 11 years is the average useful life of capital assets used in Tabula Rasa HealthCare operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for TRHC is equal to -1.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $123.888 million for Tabula Rasa HealthCare - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 20.013 million for Tabula Rasa HealthCare is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Tabula Rasa HealthCare at the current share price and the inputted number of shares is $1.3 billion.

RELATED COMPANIES Price Int.Val. Rating
ADBE Adobe Systems 239.95 239.44  hold

COMPANY NEWS

▶ Tabula Rasa Healthcare: 3Q Earnings Snapshot   [07:06AM  Associated Press]
▶ TRHCs Capstone Performance System Continues Growth   [Oct-01-18 09:50AM  GlobeNewswire]
▶ Tabula Rasa HealthCare Acquires Mediture and eClusive   [Sep-04-18 08:00AM  GlobeNewswire]
▶ Tabula Rasa Healthcare: 2Q Earnings Snapshot   [07:27PM  Associated Press]
▶ TRHCs Capstone Performance System Signs New Contracts   [Jul-11-18 03:38PM  GlobeNewswire]
▶ Tabula Rasa Healthcare: 1Q Earnings Snapshot   [May-08-18 07:09PM  Associated Press]
▶ Peak PACE Solutions to Join Capstone Performance Systems   [May-03-18 12:46PM  GlobeNewswire]
▶ Tabula Rasa Healthcare misses 4Q profit forecasts   [Mar-12-18 04:53PM  Associated Press]
▶ Tabula Rasa HealthCare CEO Presents at IBC Innovation Day   [Feb-22-18 02:43PM  GlobeNewswire]
▶ Hey Market, Can You Give Me a Minute to Catch My Breath?   [Jan-24-18 11:11AM  TheStreet.com]
▶ Is This IPO With 322% Growth Following In Facebook's Footsteps?   [Jan-23-18 11:02AM  Investor's Business Daily]
▶ Tabula Rasa Healthcare misses 3Q profit forecasts   [Nov-06-17 04:54PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.